THE SITUATION OF DRUG USING AND THE COST OF BRONCHIAL ASTHMA OUTPATIENT TREATMENT COVERED BY MEDICAL INSURANCE AT CAN THO TUBERCULOSIS AND LUNG DISEASE HOSPITAL IN 2020
Main Article Content
Abstract
Background: The cost of treating asthma accounts for about 5.5-14.5% of the patient's total family income. The cost of treating asthma for each year according to the control level of bronchial asthma. Objectives: To determine the rate of used drug types and the treatment cost for bronchial asthmathe outpatients having health insurance at Can Tho Tuberculosis and Lung Disease Hospital in 2020. Materials and methods: A cross-sectional descriptive study on the prescription and the treatment cost of 142 medical records of bronchial asthma outpatients at Can Tho Tuberculosis and Lung Disease Hospital from January 2020 to December 2020. Results: The rate of used drugs: bronchodilator group was 10.95%, group of corticosteroids was 3.17%, group of drugs that combine bronchodilators and corticosteroids was 40.92%, and antibiotic was 3.75%; Other drugs included anti-allergy medicine, cough medicine, vitamin, etc were 41.21%. The treatment costs according to the control level of bronchial asthma were 477,367 VND; 489,201 VND; 520,246 VND; 520,527 VND. Conclusions: Outpatients diagnosed and treated asthma exacerbations covered by health insurance at Can Tho Tuberculosis and Lung Disease Hospital using combined bronchodilators with corticosteroids 40.92%, the covered treatment fee depended on the control level of bronchial asthma and the prescribed premium.
Article Details
Keywords
bronchial asthma, cost
References
2. Châu N. Q. (2017), Hướng dẫn chẩn đoán và điều trị Hen phế quản, Hội Hô hấp Việt Nam. Bệnh viện Bạch Mai. Trung tâm Hô hấp Hà Nội, pp. 1-32.
3. Trần Thị Minh Tâm (2019), Phân Tích chi phí điều trị hen phế quản tại bệnh viện quận Phú Nhuân giai đoạn 2014-2018, Luận án Chuyên Khoa II, Đại học Y Dược thành phố Hồ Chí Minh.
4. Nguyễn Ngọc Bảo Thi (2014), Đánh giá gánh nặng kinh tế trong điều trị hen suyễn tại Việt Nam theo quan điểm của bệnh nhân, Đại học Y Dược Thành phố Hồ Chí Minh, pp. 1-94.
5. Bavbek S et al. (2011), "A cost-of-illness study estimating the direct cost per asthma exacerbation in Turkey", Respir Med. 105, pp. 541–548.
6. Eduardo Costa, Rosangela Caetano, Guilherme Loureiro Werneck, Maurício Bregman, Denizar Vianna Araújo, and etal. (2018), Estimated cost of asthma in outpatient treatment: a real-world study. Rev Saude Publica, pp. 1-10.
7. Ehteshami-Afshar S et al. (2016), "The global economic burden of asthma and chronic obstructive pulmonary disease", Int J Tuberc Lung Dis., 20 (1), pp. 11-23.
8. Global Initiative for Asthma (2016), "Global Strategy for asthma management and prevention", GINA, pp. 1-20.
9. Global Strategy for Asthma Management and Prevention, 2019 [home page on the Internet]. Global initiative for asthma; 2019. Available from: https://ginasthma.org/. Accessed September 1, 2019.
10. Ivanova JI et al. (2012), "Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma", Allergy Clin Immunol. 129, pp. 1229–1235.
11. de Miguel-Díez J et al. (2014), “National trends in hospital admissions for asthma exacerbations among pediatric and young adult population in Spain (2002-2010)”, Respir Med. 108 (7), pp. 983-991.